Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer launches SpringWorks
by Ryan Cross
October 2, 2017
| A version of this story appeared in
Volume 95, Issue 39
New York City-based start-up SpringWorks Therapeutics has sprouted from Pfizer with the goal of providing a home for drugs orphaned by other companies but ready for a Phase II or III clinical study. President Lara S. Sullivan left her position as a Pfizer vice president to found SpringWorks, which garnered $103 million in series A funds from Bain Capital Life Sciences, Pfizer, and others. Its first move is to drive four potential therapies abandoned by Pfizer into advanced clinical trials for desmoid tumors, neurofibromatosis, hereditary xerocytosis, and posttraumatic stress disorder.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X